Skip to contentS
Sanara MedTech Inc.
S
SMTISanara MedTech Inc. Q3 2025 · 10-Q
Revenue$26.33M$26.33M+21.5% vs Q3 2024 Net Income-$30.41M-$30.41MN/M vs Q3 2024 EPS Diluted-$3.40-$3.40N/M vs Q3 2024 Gross Profit$24,459,605+24.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sanara MedTech Inc. · CIK 714256 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,176,441+6.1% Free Cash Flowderived$1,116,958−45.3% Margins · derivedGross margin92.9%+2.1 pt vs Q3 2024
Operating margin11.2%+7.6 pt vs Q3 2024
Net margin-115.5%−102.3 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end